Sun Pharma Q3FY08 Results

Sun Pharmaceutical Industries Ltd has announced the following Unaudited results for the quarter ended December 31, 2007:

The Company has posted a profit after tax of Rs 3459.30 million for the quarter ended December 31, 2007 as compared to Rs 1651.30 million for the quarter ended December 31, 2006. Total Income has increased from Rs 6119.70 million for the quarter ended December 31, 2006 to Rs 9603.30 million for the quarter ended December 31, 2007.

The Consolidated Results are as follows

The Group has posted a net profit after minority interest of Rs 3183.50 million for the quarter ended December 31, 2007 as compared to Rs 1988.50 million for the quarter ended December 31, 2006. Total Income has increased from Rs 6035.90 million for the quarter ended December 31, 2006 to Rs 8218.80 million for the quarter ended December 31, 2007.

Sun Pharmaceutical Industries Q2 results

Sun Pharmaceutical Industries Ltd has announced the following Unaudited results for the quarter ended September 30, 2007:

The Company has posted a profit after tax of Rs 1948.30 million for the quarter ended September 30, 2007 as compared to Rs 1601.10 million for the quarter ended September 30, 2006. Total Income has increased from Rs 5930.60 million for the quarter ended September 30, 2006 to Rs 7740.90 million for the quarter ended September 30, 2007.

The Consolidated results are as follows:

The Group has posted a net profit after minority interest of Rs 2185.50 million for the quarter ended September 30, 2007 as compared to Rs 1864.20 million for the quarter ended September 30, 2006. Total Income has increased from Rs 5763.50 million for the quarter ended September 30, 2006 to Rs 6790.00 million for the quarter ended September 30, 2007.

Sun Pharma gets USFDA approval

Sun Pharmaceutical Industries Ltd has announced that USFDA has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis Exelon®, rivastigmine tartrate capsules.

These generic rivastigmine capsules are AB-rated equivalent of Novartis Exelon® Capsules and include four strengths: 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base). These strengths of Exelon® have annual sales of approximately USD 200 million in the US.

Sun Pharma, being one of the first-to-file an ANDA for generic Exelon® with a para IV certification, shares a 180-day marketing exclusivity, in view of the ongoing litigation with Novartis on this product, the Company is evaluating all its launch options.

Rivastgmine tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia associated with Parkinson's disease.

Sun Pharmaceutical Industries won't get sued

Sun Pharmaceutical Industries Ltd on October 16, 2007 has announced receipt of a Covenant Not to Sue from Wyeth over Sun Pharma’s Abbreviated New Drug Application (ANDA) for generic venlafaxine extended release tablets with multiple para IV certifications.

This ANDA for generic venlafaxine extended release tablets, AB-rated equivalent of Wyeth’s Effexor XR® Capsules, includes three strengths: 37.5 mg, 75 mg and 150 mg and is based on Innovative technology for extended release tablets. These strengths of Effexor XR® Capsules have annual sales approximately USD 2.6 billion in the US.

As per the covenant, Wyeth covenants not to sue Sun under any claims of US Patent Nos. 6,274,171, 6,4013,120 and 6,419,958.

Venlafaxine is an antidepressant of the serotonin-noreplnephrine reuptake inhibitor (SNRI) class.

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Ltd has announced that USFDA has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis Trileptal®, oxcarbazepine tablets.

These generic oxcarbazepine tablets are AB-rated equivalent of Novartis Trileptal® Tablets and include three strengths: 150 mg, 300 mg and 600 mg. These strengths of Trileptal® have annual sales of approximately USD 640 million in the US.

Sun Pharma, being one of the first-to-file an ANDA for generic Trileptal® with a para IV certification, shares a 180 day marketing exclusivity. No action for patent infringement has been brought against Sun Pharma.

Oxcarbazepinc is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures.

The Company expects to reach the market shortly with these products.

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Ltd has informed about the Press Release of Caraco Pharmaceutical Laboratories Ltd, i.e. Company's U. S. subsidiary company dated September 26, 2007, as follows :

"Caraco Pharmaceutical Laboratories, Ltd, (Amex: CPD) on September 26, 2007 has announced that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Methimazole Tablets USP, 5 mg and 10 mg (Methimazole).

Methimazole is indicated in the medical treatment of hyperthyroidism. Caraco's Methimazole is therapeutically equivalent to the FDA reference listed drug (RLD) listed in the Orange Book, Methimazole Tablets USP, 5 mg and 10 mg, respectively. According to IMS Data, for the twelve months ended June 2007, Methimazole had annual sales of approximately $21 million.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to receive this approval from the FDA. This marks the third approval in the last 30 days and the sixth approval this quarter. This is in addition to the two tentative approvals granted by the FDA during the period. One of the main driver's of our growth is to continue to expand and strengthen our product portfolio. This will bring our total product selection to 41
different products represented by 86 various strengths."

Detroit-based Caraco Pharmaceutical Laboratories Ltd, develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers."